Palbociclib em combinação com terapia endócrina versus capecitabina em câncer de mama metastático receptor hormonal-positivo, receptor 2 do fator de crescimento epidérmico humano-negativo e resistente a inibidores de aromatase: um ensaio clínico randomizado de fase III—PEARL

Martín et al. (Ter,) estudaram esta questão.

www.synapsesocial.com/papers/69dd489b99c691022d99bb6a — DOI: https://doi.org/10.1016/j.annonc.2020.12.013

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer· 2019 · 836 citations
2. Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and <i>ESR1</i> mutations (mus) in circulating tumor DNA (ctDNA).· 2016 · 21 citations
3. An Overview of Statistical Planning to Address Subgroups in Confirmatory Clinical Trials· 2014 · 29 citations
4. Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets· 2012 · 2,210 citations
5. Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer· 1999 · 791 citations